285 related articles for article (PubMed ID: 21540474)
1. Spindle poisons and cell fate: a tale of two pathways.
Matson DR; Stukenberg PT
Mol Interv; 2011 Apr; 11(2):141-50. PubMed ID: 21540474
[TBL] [Abstract][Full Text] [Related]
2. Mitosis and apoptosis: how is the balance set?
Topham CH; Taylor SS
Curr Opin Cell Biol; 2013 Dec; 25(6):780-5. PubMed ID: 23890995
[TBL] [Abstract][Full Text] [Related]
3. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
Huang HC; Shi J; Orth JD; Mitchison TJ
Cancer Cell; 2009 Oct; 16(4):347-58. PubMed ID: 19800579
[TBL] [Abstract][Full Text] [Related]
4. Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer.
Dalton WB; Yang VW
Future Oncol; 2009 Nov; 5(9):1363-70. PubMed ID: 19903065
[TBL] [Abstract][Full Text] [Related]
5. Adapt or die: how eukaryotic cells respond to prolonged activation of the spindle assembly checkpoint.
Rossio V; Galati E; Piatti S
Biochem Soc Trans; 2010 Dec; 38(6):1645-9. PubMed ID: 21118141
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Choi M; Kim W; Cheon MG; Lee CW; Kim JE
Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
[TBL] [Abstract][Full Text] [Related]
7. No way out for tumor cells.
Rieder CL; Medema RH
Cancer Cell; 2009 Oct; 16(4):274-5. PubMed ID: 19800571
[TBL] [Abstract][Full Text] [Related]
8. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
[TBL] [Abstract][Full Text] [Related]
9. The mitotic checkpoint in cancer therapy.
Tao W
Cell Cycle; 2005 Nov; 4(11):1495-9. PubMed ID: 16258280
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons.
Yamada HY; Gorbsky GJ
Mol Cancer Ther; 2006 Jan; 5(1):29-38. PubMed ID: 16432160
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic.
Henriques AC; Silva PMA; Sarmento B; Bousbaa H
Sci Rep; 2021 Feb; 11(1):4139. PubMed ID: 33603057
[TBL] [Abstract][Full Text] [Related]
12. Mitotic slippage: an old tale with a new twist.
Sinha D; Duijf PHG; Khanna KK
Cell Cycle; 2019 Jan; 18(1):7-15. PubMed ID: 30601084
[TBL] [Abstract][Full Text] [Related]
13. MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules.
Zhang Z; Meng T; He J; Li M; Tong LJ; Xiong B; Lin L; Shen J; Miao ZH; Ding J
Invest New Drugs; 2010 Dec; 28(6):715-28. PubMed ID: 19705064
[TBL] [Abstract][Full Text] [Related]
14. A simplified Bcl-2 network model reveals quantitative determinants of cell-to-cell variation in sensitivity to anti-mitotic chemotherapeutics.
Kueh HY; Zhu Y; Shi J
Sci Rep; 2016 Nov; 6():36585. PubMed ID: 27811996
[TBL] [Abstract][Full Text] [Related]
15. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
16. Salt-inducible kinase 3 is a novel mitotic regulator and a target for enhancing antimitotic therapeutic-mediated cell death.
Chen H; Huang S; Han X; Zhang J; Shan C; Tsang YH; Ma HT; Poon RY
Cell Death Dis; 2014 Apr; 5(4):e1177. PubMed ID: 24743732
[TBL] [Abstract][Full Text] [Related]
17. Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.
Levrier C; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Sadowski MC; Nelson CC
Cell Cycle; 2018; 17(5):652-668. PubMed ID: 28749250
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
19. Mitotic drug targets.
Kaestner P; Bastians H
J Cell Biochem; 2010 Oct; 111(2):258-65. PubMed ID: 20518069
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents.
Birk M; Bürkle A; Pekari K; Maier T; Schmidt M
Int J Cancer; 2012 Feb; 130(4):798-807. PubMed ID: 21387302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
